A 24-week randomised, double-blind, parallel-group, multi-centre, placebo-controlled phase III trial to evaluate the efficacy and safety of dapagliflozin as monotherapy in Japanese subjects with Type 2 diabetes who have inadequate glycemic control with diet and exercise
